[1]Gwee KA, Ghoshal UC, Chen M. Irritable bowel syndrome in Asia: Pathogenesis, natural history, epidemiology, and management[J] . J Gastroenterol Hepatol, 2018, 33(1): 99-110.
[2]Radovanovic-Dinic B, Tesic-Rajkovic S, Grgov S, et al. Irritable bowel syndrome - from etiopathogenesis to therapy [J]. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub, 2018, 162(1): 1-9.
[3]Craig O. New therapies in Irritable Bowel Syndrome: what works and when [J]. Curr Opin Gastroenterol, 2018, 34(1): 50-56.
[4]Ohman L, Simren M. New insights into the pathogenesis and pathophysiology of irritable bowel syndrome [J]. Dig Liver Dis, 2007, 39(3): 201-215.
[5]Martin-Vias JJ, Quigley EM. Immune response in irritable bowel syndrome: A systematic review of systemic and mucosal inflammatory mediators [J]. J Dig Dis, 2016, 17(9): 572-581.
[6]Boeckxstaens GE, Wouters MM. Neuroimmune factors in functional gastrointestinal disorders: A focus on irritable bowel syndrome [J]. Neurogastroenterol Motil, 2017, 29(6). doi: 10.1111/nmo.13007.
[7]方亮, 张凡勇, 吴继雄. 肠易激综合征患者结直肠黏膜降钙素基因相关肽和P物质表达及与临床症状的相关性 [J]. 疑难病杂志, 2017, 16(1): 64-67.
[8]Boyer J, Saint-Paul MC, Dadone B, et al. Inflammatory cell distribution in colon mucosa as a new tool for diagnosis of irritable bowel syndrome: A promising pilot study [J]. Neurogastroenterol Motil, 2018, 30(1). doi: 10.1111/nmo.13223.
[9]Bashashati M, Moossavi S, Cremon C, et al. Colonic immune cells in irritable bowel syndrome: A systematic review and meta-analysis [J]. Neurogastroenterol Motil, 2018, 30(1). doi: 10.1111/nmo.13192.
[10]Bednarska O, Walter SA, Casado-Bedmar M, et al. Vasoactive intestinal polypeptide and mast cells regulate increased passage of colonic bacteria in patients with irritable bowel syndrome [J]. Gastroenterology, 2017, 153(4): 948-960.e3.
[11]Wouters MM, Vicario M, Santos J. The role of mast cells in functional GI disorders [J]. Gut, 2016, 65(1): 155-168.
[12]白连霞, 郝木红. 酮替芬联合布地奈德治疗支气管哮喘的临床疗效及其安全性[J]. 临床合理用药杂志, 2018, 11(21): 15-16.
[13]Mearin F, Lacy BE, Chang L, et al. Bowel disorders [J]. Gastroenterology, 2016, pii: S0016-5085(16)00222-5.
[14]Ballou S, Keefer L. The impact of irritable bowel syndrome on daily functioning: Characterizing and understanding daily consequences of IBS [J]. Neurogastroenterol Motil, 2017, 29(4), doi: 10.1111/nmo.12982.
[15]Weaver KR, Melkus GD, Henderson WA. Irritable bowel syndrome [J]. Am J Nurs, 2017, 117(6): 48-55.
[16]Yoon H. Mast cell may be the master key to solve the mystery of pathogenesis of irritable bowel syndrome [J]. Gut Liver, 2016, 10(3): 325-326.
[17]Barbara G, Wang B, Stanghellini V, et al. Mast cell-dependent excitation of visceral- nociceptive sensory neurons in irritable bowel syndrome [J]. Gastroenterology, 2007, 132(1): 26-37.
[18]An S, Zong G, Wang Z, et al. Activation of protease-activated receptor 4 of mast cells could downregulate proinflammatory cytokines in irritable bowel syndrome [J]. Gut, 2017, 66(11): 2040-2042.
[19]Cremon C, Carini G, Wang B, et al. Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome [J]. Am J Gastroenterol, 2011, 106(7): 1290-1298.
[20]Patman G. IBS: Mast cells cause nerves to sprout in patients with IBS [J]. Nat Rev Gastroenterol Hepatol, 2015, 12(4): 189.
[21]Dothel G, Barbaro MR, Boudin H, et al. Nerve fiber outgrowth is increased in the intestinal mucosa of patients with irritable bowel syndrome [J]. Gastroenterology, 2015, 148(5): 1002-1011.e4.
[22]Hughes PA, Zola H, Penttila IA, et al. Immune activation in irritable bowel syndrome: can neuroimmune interactions explain symptoms [J]. Am J Gastroenterol, 2013, 108(7): 1066-1074.
[23]Vicario M, González-Castro AM, Martínez C, et al. Increased humoral immunity in the jejunum of diarrhoea-predominant irritable bowel syndrome associated with clinical manifestations [J]. Gut, 2015, 64(9): 1379-1388.
[24]Piche T. Tight junctions and IBS-the link between epithelial permeability, low-grade inflammation, and symptom generation [J]. Neurogastroenterol Motil, 2014, 26(3): 296-302.
[25]Liu DR, Xu XJ, Yao SK. Increased intestinal mucosal leptin levels in patients with diarrhea-predominant irritable bowel syndrome [J]. World J Gastroenterol, 2018, 24(1): 46-57.
[26]Braak B, Klooker TK, Wouters MM, et al. Mucosal immune cell numbers and visceral sensitivity in patients with irritable bowel syndrome: is there any relationship [J]. Am J Gastroenterol, 2012, 107(5): 715-726.
[27]Klooker TK, Braak B, Koopman KE, et al. The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome [J]. Gut, 2010, 59(9): 1213-1221.
[28]Martínez C, Lobo B, Pigrau M, et al. Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier [J]. Gut, 2013, 62(8): 1160-1168. |